Experimental Data Snapshot
Starting Model:experimental
View more details
(2015) Angew Chem Int Ed Engl 54: 15410
Peptide stapling is a method for designing macrocyclic alpha-helical inhibitors of protein-protein interactions. However, obtaining a cell-active inhibitor can require significant optimization. We report a novel stapling technique based on a double strain-promoted azide-alkyne reaction, and exploit its biocompatibility to accelerate the discovery of cell-active stapled peptides. As a proof of concept, MDM2-binding peptides were stapled in parallel, directly in cell culture medium in 96-well plates, and simultaneously evaluated in a p53 reporter assay. This in situ stapling/screening process gave an optimal candidate that showed improved proteolytic stability and nanomolar binding to MDM2 in subsequent biophysical assays. α-Helicity was confirmed by a crystal structure of the MDM2-peptide complex. This work introduces in situ stapling as a versatile biocompatible technique with many other potential high-throughput biological applications.
 Explore in 3D: Structure |Sequence Annotations |Electron Density |Validation Report |Ligand Interaction (P07)
Biological assembly 1 assigned by authors and generated by PISA (software)
Macromolecule Content 
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| E3 UBIQUITIN-PROTEIN LIGASE MDM2 | 97 | Homo sapiens | Mutation(s): 2  EC: 6.3.2.19 (PDB Primary Data), 2.3.2.27 (UniProt) | ![]() | |
UniProt & NIH Common Fund Data Resources | |||||
Find proteins for Q00987 (Homo sapiens) Explore Q00987  Go to UniProtKB:  Q00987 | |||||
PHAROS:  Q00987 GTEx:  ENSG00000135679  | |||||
Entity Groups  | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | Q00987 | ||||
Sequence AnnotationsExpand | |||||
| |||||
Find similar proteins by: Sequence | 3D Structure
Entity ID: 2 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| STAPLED PEPTIDE | 12 | synthetic construct | Mutation(s): 0  | ![]() | |
Entity Groups  | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
Sequence AnnotationsExpand | |||||
| |||||
| Ligands 1 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Name / Formula / InChI Key | 2D Diagram | 3D Interactions | |
| P07 Query on P07 Download Ideal Coordinates CCD File  | C [auth B] | 1,8-DIETHYL-1,8-DIHYDRODIBENZO[3,4:7,8][1,2,3]TRIAZOLO[4',5':5,6]CYCLOOCTA[1,2-D][1,2,3]TRIAZOLE C20 H18 N6 YRZRZRBFIALCLI-MKVCYXFSSA-N | |||
| Modified Residues 1 Unique | |||||
|---|---|---|---|---|---|
| ID | Chains | Type | Formula | 2D Diagram | Parent |
| LAY Query on LAY | B | L-PEPTIDE LINKING | C8 H15 N O3 | LEU | |
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 36.821 | α = 90 |
| b = 36.821 | β = 90 |
| c = 177.416 | γ = 90 |
| Software Name | Purpose |
|---|---|
| REFMAC | refinement |
| PROTEUM2 | data reduction |
| PROTEUM2 | data scaling |
| PHASER | phasing |
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729. RCSB PDB uses resources of the National Energy Research Scientific Computing Center (NERSC), a Department of Energy User Facility.